4534 — Mochida Pharmaceutical Co Balance Sheet
0.000.00%
- ¥130bn
- ¥109bn
- ¥117bn
Annual balance sheet for Mochida Pharmaceutical Co, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.
2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | 2026 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Yuho | Yuho | Yuho | Yuho | Tanshin |
| Standards: | JAS | JAS | JAS | JAS | — |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 61,914 | 60,509 | 46,789 | 51,150 | 31,057 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 31,676 | 27,806 | 34,838 | 31,617 | 36,478 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 121,448 | 117,379 | 116,662 | 119,669 | 119,021 |
| Net Property, Plant And Equipment | 14,528 | 15,049 | 15,874 | 15,940 | 16,302 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 163,139 | 158,831 | 158,800 | 160,121 | 182,720 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 29,856 | 27,258 | 26,073 | 24,902 | 27,734 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 34,493 | 32,056 | 30,833 | 29,427 | 42,394 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 128,646 | 126,775 | 127,967 | 130,694 | 140,326 |
| Total Liabilities & Shareholders' Equity | 163,139 | 158,831 | 158,800 | 160,121 | 182,720 |
| Total Common Shares Outstanding |